findmyKOL

John Botson, MD, RPH

Basic profile

Alaska Breast Care & Surgery

ORCIDNone on fileNPI
RegionAnchorage, AK · WestSpecialtyRheumatologyFocusRheumatology/Immunology
ActivityNot yet indexedfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publicationSee ScholarshipOnline presenceNot yet checkedPayments2021 onwardNIH fundingNot yet indexedWhy? →

John Botson is a Rheumatology/Immunology pharmacist affiliated with Alaska Breast Care & Surgery. OpenAlex indexes 34 publications with 354 citations (h-index 10).

Overview

Scholarship

indexed output and impact (OpenAlex)
34publications

Distinct works indexed by OpenAlex.

354citations

Total citations across indexed works.

10h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
101companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments

Industry payments

101 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

101 companies with payments on record in CMS Open Payments (2021 onward), matched to this physician's NPI. The itemized breakdown by company, amount and year is part of the full profile. Why? →

Medicare prescribing footprint (2023)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Cancer & immunology

    68.7%
    Interleukin-6 Receptor Antagonist45.6%
    Tocilizumab100%Actemra Actpen0%Kevzara0%
    Part D + Part B<11 patients
    TNF inhibitor19.4%
    Infliximab64%Golimumab36%Humira(Cf) Pen0%Enbrel Sureclick0%Enbrel0%Humira(Cf)0%
    Part D + Part B<11 patients

    + 8 more classes in this area

  • Musculoskeletal

    30.2%
    Other drugs affecting bone structure and mineralization26.7%
    Romosozumab-aqqg100%
    Part B, office-administered36 patients
    RANK Ligand Inhibitor3.3%
    Denosumab100%
    Part B, office-administered56 patients

    + 4 more classes in this area

  • Dermatology

    0.5%
    Corticosteroid0.5%
    Triamcinolone acetonide88%Methylprednisolone sodium succinate12%
    Part B, office-administered71 patients
Where care is delivered (Part B)0% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”